ALT-803 IL-15 Soluble Fusion Molecules and Methods
Summary
The USPTO published patent application US20260092097A1 for ALT-803, a complex of interleukin-15 (IL-15) superagonist mutant and dimeric IL-15 receptor α/Fc fusion protein. The application covers compositions and methods for enhancing immune response against neoplasia (multiple myeloma, melanoma, lymphoma) or viral infections (HIV). Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han. Application filed June 25, 2025.
What changed
USPTO published patent application US20260092097A1 (Kind A1) for ALT-803, an IL-15 superagonist complex fused to dimeric IL-15 receptor α/Fc protein. The patent covers compositions and methods for treating neoplasia including multiple myeloma, melanoma, and lymphoma, as well as viral infections such as HIV. The application includes CPC classifications spanning immunology (C07K 14/7155), cancer therapeutics (A61K 38/1793), and recombinant DNA methods (C12N 15/09).
Patent applicants and biotechnology companies developing IL-15-based immunotherapies should review this publication for potential prior art implications. The filing date is June 25, 2025, with Application No. 19248938. This is a publication of a pending application and does not itself impose compliance obligations, but may affect freedom-to-operate analyses for competing therapeutic programs.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME
Application US20260092097A1 Kind: A1 Apr 02, 2026
Inventors
Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han
Abstract
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
CPC Classifications
C07K 14/7155 A61K 38/1793 A61K 38/2086 A61K 39/3955 A61K 45/06 C07K 14/5443 C07K 16/18 C07K 16/2887 C12N 15/09 C12N 15/62 C12P 21/00 A61K 38/00 C07K 2317/622 C07K 2317/732 C07K 2319/00 C07K 2319/21 C07K 2319/22 C07K 2319/30
Filing Date
2025-06-25
Application No.
19248938
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.